U.S. Markets
Revolution Medicines (RVMD) announces European Commission approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy
ORIGINAL · NewsquawkRevolution Medicines (RVMD) announces European Commission approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy
StockNow breaking-news AI analysis
The European Commission approved Rasonque for eligible metastatic pancreatic cancer patients; reported third-quarter net product revenue was $197.6 million, while European pricing and reimbursement remain country-specific decisions.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
